Diabetes 2009
Disclosure

Disclosure Policy
It is the policy of Yale University School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All participants in this program are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved prior to this activity.

Disclosure
In meeting the requirements of full disclosure and in compliance with the Accreditation Council for Continuing Medical Education Essentials, Standards for Commercial Support, and Guidelines, the following information has been provided by our editors regarding potential conflicts of interest: Robert S. Sherwin, M.D. is engaged in research activities supported by Bayer, Chiron, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Takeda Pharmaceuticals North America, Inc. Silvio E. Inzucchi, M.D. is a consultant to Aventis, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Takeda Pharmaceuticals America, Inc. In accordance with the 2004 ACCME Standards for Commercial Support, a peer review process has been established for this program and all Conflict of Interest issues (if any) have been resolved.

This program is supported in part through educational grants from Takeda Pharmaceuticals North America, Inc., Merck & Co., Inc., Novo Nordisk®, Amylin Pharamaceuticals, Inc. and Eli Lilly and Company. It is understood that supporters will in no way control the content of materials on this site.

Target Audience
Invited participants are cardiologists and physicians who have a primary interest in and care for patients with Type 2 diabetes.

Educational Methods
Fax and Email: At the end of each conference day, a newsletter will be faxed or sent by e-mail to the office of subscribing physicians. Shortly after each conference concludes, participants will receive a Diabetes booklet for the conference containing all of the newsletters, a program highlights summary from the program co-editors, a course evaluation form, and a post-test.

On-Line: At the end of each conference day, the newsletter will be downloaded to the Yale CME web site where subscribers may view the information and, if they desire, obtain CME credits on line. See information regarding the Course at Using the Course and Getting Credit.

Evaluation
A course evaluation form will provide participants with the opportunity to review the program content and method of delivery and to identify future educational needs and possible bias in the presentation.

Accreditation
This program has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of Yale University School of Medicine.

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The American Medical Association has determined that physicians not licensed in the US who participate in the CME activity are eligible for AMA PRA Category 1 Credit™.

Designation Statement
The Yale School of Medicine designates this educational activity for a maximum of 5.5 AMA PRA Category 1 Credits™ per monograph. Physicians should only claim credit commensurate with the extent of their participation in the activity.